The EU's drug regulator said Tuesday that blood clots should be listed as a "very rare" side effect of the Johnson & Johnson coronavirus vaccine but that its benefits still outweighed the risks.
The European Medicines Agency said in a statement it had found a "possible link" between the jab and the clot, and that its safety committee "concluded that these events should be listed as very rare side effects of the vaccine".